AU2010249881B2 - Compositions comprising cationic amphiphiles and colipids for delivering therapeutics molecules - Google Patents

Compositions comprising cationic amphiphiles and colipids for delivering therapeutics molecules Download PDF

Info

Publication number
AU2010249881B2
AU2010249881B2 AU2010249881A AU2010249881A AU2010249881B2 AU 2010249881 B2 AU2010249881 B2 AU 2010249881B2 AU 2010249881 A AU2010249881 A AU 2010249881A AU 2010249881 A AU2010249881 A AU 2010249881A AU 2010249881 B2 AU2010249881 B2 AU 2010249881B2
Authority
AU
Australia
Prior art keywords
composition
nucleic acid
cholesterol
lipid
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010249881A
Other languages
English (en)
Other versions
AU2010249881A1 (en
Inventor
Kunyuan Cui
Dong Liang
David Sweedler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AGAVE PHARMA Inc
Original Assignee
AGAVE PHARMA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AGAVE PHARMA Inc filed Critical AGAVE PHARMA Inc
Publication of AU2010249881A1 publication Critical patent/AU2010249881A1/en
Application granted granted Critical
Publication of AU2010249881B2 publication Critical patent/AU2010249881B2/en
Assigned to AGAVE PHARMA, INCORPORATED reassignment AGAVE PHARMA, INCORPORATED Request for Assignment Assignors: CUI, KUNYUAN, LIANG, DONG, SWEEDLER, DAVID
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2010249881A 2009-05-16 2010-05-16 Compositions comprising cationic amphiphiles and colipids for delivering therapeutics molecules Active AU2010249881B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17896209P 2009-05-16 2009-05-16
US61/178,962 2009-05-16
PCT/US2010/035049 WO2010135207A1 (en) 2009-05-16 2010-05-16 Compositions comprising cationic amphiphiles and colipids for delivering therapeutics molecules

Publications (2)

Publication Number Publication Date
AU2010249881A1 AU2010249881A1 (en) 2012-01-19
AU2010249881B2 true AU2010249881B2 (en) 2015-01-22

Family

ID=43126456

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010249881A Active AU2010249881B2 (en) 2009-05-16 2010-05-16 Compositions comprising cationic amphiphiles and colipids for delivering therapeutics molecules

Country Status (7)

Country Link
US (1) US9080186B2 (https=)
EP (1) EP2430168B1 (https=)
JP (1) JP5675784B2 (https=)
CN (1) CN102985548B (https=)
AU (1) AU2010249881B2 (https=)
CA (1) CA2762095A1 (https=)
WO (1) WO2010135207A1 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815818B2 (en) 2008-07-18 2014-08-26 Rxi Pharmaceuticals Corporation Phagocytic cell delivery of RNAI
EP2342340A1 (en) 2008-09-22 2011-07-13 Rxi Pharmaceuticals Corporation Rna interference in skin indications
WO2010078536A1 (en) 2009-01-05 2010-07-08 Rxi Pharmaceuticals Corporation Inhibition of pcsk9 through rnai
IN2012DN00570A (https=) 2009-07-14 2015-06-12 Polypid Ltd
EP2525778B1 (en) 2010-01-19 2018-08-01 Polypid Ltd. Sustained-release nucleic acid matrix compositions
FR2994849B1 (fr) * 2012-08-30 2015-01-02 Commissariat Energie Atomique Formulation pour la delivrance de sequences nucleotidiques susceptibles de moduler des mecanismes endogenes d'arn interferents
US10253315B2 (en) 2012-08-30 2019-04-09 Commissariat A L'energie Atomique Et Aux Energies Alternatives Method for transfection of nucleic acids into eukaryotic cells in 3D scaffold
FR2998899B1 (fr) * 2012-11-30 2015-07-17 Commissariat Energie Atomique Methode de criblage a haut-debit pour l'identification de biomarqueurs, cibles therapeutiques ou d'agents therapeutiques
EP2719765A1 (de) * 2012-10-11 2014-04-16 Secutech International Pte. Ltd. Ex vivo-Verfahren zur Einbringung von Nukleinsäuren in Zellen
EP2913047B1 (en) * 2012-10-29 2019-05-08 Cardio Incorporated Pulmonary disease-specific therapeutic agent
CN105452465B (zh) * 2013-07-31 2019-06-21 奇比艾企业有限公司 鞘脂-聚烷基胺-寡核苷酸化合物
WO2015184326A1 (en) * 2014-05-30 2015-12-03 Cerulean Pharma Inc. Conjugates, particles, compositions, and related methods
US20150368648A1 (en) * 2014-06-20 2015-12-24 Yale University Compositions and methods of inhibiting gene expression in a lung
KR101671864B1 (ko) * 2014-08-29 2016-11-04 세종대학교 산학협력단 요오드화 오일을 함유하는 양이온성 에멀젼 및 바이러스 벡터의 유전자 전달 증진을 위한 이의 용도
CN104922141B (zh) * 2015-05-28 2016-05-25 厦门成坤生物技术有限公司 一种用于治疗乙型病毒性肝炎的siRNA组合物
CN105079021A (zh) * 2015-08-03 2015-11-25 厦门成坤生物技术有限公司 包含m10c1化合物与活性成分的组合物及其制备方法
JP6948313B6 (ja) 2015-09-17 2022-01-14 モデルナティエックス インコーポレイテッド 治療剤の細胞内送達のための化合物および組成物
LT3394030T (lt) 2015-12-22 2022-04-11 Modernatx, Inc. Junginiai ir kompozicijos terapinei medžiagai teikti intraceliuliniu būdu
EP3423438A4 (en) * 2016-03-01 2020-05-06 Molecular Transfer, Inc. PLANT VIRUS MOTOR PROTEINS AND METHOD FOR USE THEREOF
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
CA3055653A1 (en) * 2017-03-15 2018-09-20 Modernatx, Inc. Lipid nanoparticle formulation
WO2018170322A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Crystal forms of amino lipids
EP4186888B1 (en) 2017-03-15 2025-11-26 ModernaTX, Inc. Compound and compositions for intracellular delivery of therapeutic agents
US12544344B2 (en) 2017-04-19 2026-02-10 Phio Pharmaceuticals Corp. Topical delivery of nucleic acid compounds
WO2018232120A1 (en) 2017-06-14 2018-12-20 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
CN107802508A (zh) * 2017-11-01 2018-03-16 武汉百思凯瑞纳米科技有限公司 一种阳离子脂质体纳米组合物及其制备方法和应用
KR102056144B1 (ko) 2018-03-08 2019-12-16 주식회사 파마리서치프로덕트 Dna 단편 혼합물이 고농도로 함유된 유동성을 갖는 액제 조성물 및 이의 제조방법
EP3852764A4 (en) * 2018-09-19 2022-06-15 ModernaTX, Inc. STEROL ANALOGUES AND USES THEREOF
WO2020061367A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
JP2022501371A (ja) * 2018-09-19 2022-01-06 モデルナティエックス インコーポレイテッドModernaTX, Inc. ステロールの精製
AU2020350759A1 (en) 2019-09-19 2022-03-31 Modernatx, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
CN111904934B (zh) * 2020-09-21 2022-02-25 中国医学科学院医药生物技术研究所 miRNA185抑制剂的脂质体及其制法
CA3094859A1 (en) * 2020-10-01 2022-04-01 Entos Pharmaceuticals Inc. Proteolipid vesicles formulated with fusion associated small transmembrane proteins
CN120775847A (zh) 2021-10-20 2025-10-14 厦门甘宝利生物医药有限公司 Agt抑制剂及其用途
CN118984831A (zh) * 2022-03-15 2024-11-19 富士胶片株式会社 化合物及脂质组合物
WO2023229023A1 (ja) * 2022-05-25 2023-11-30 学校法人 名城大学 粉末剤及びその製造方法
CN116814621B (zh) 2022-08-05 2025-09-09 厦门甘宝利生物医药有限公司 一种抑制apoc3基因表达的rna抑制剂及其应用
CN115197431B (zh) * 2022-09-15 2022-11-29 清华大学 脂质偶联完全可降解水溶性聚合物的合成及应用
CN115851723B (zh) 2022-10-24 2023-10-03 厦门甘宝利生物医药有限公司 一种抑制lpa基因表达的rna抑制剂及其应用
WO2025021083A1 (en) * 2023-07-24 2025-01-30 National Institute Of Biological Sciences, Beijing Lipid nanoparticle compositions for localized treatment of skin diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050175682A1 (en) * 2003-09-15 2005-08-11 Protiva Biotherapeutics, Inc. Polyethyleneglycol-modified lipid compounds and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58500845A (ja) 1981-06-04 1983-05-26 デラウェア・ケミカルス・コーポレーション ポンプ
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4778810A (en) 1987-01-08 1988-10-18 Nastech Pharmaceutical Co., Inc. Nasal delivery of caffeine
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
ES2061416T3 (es) 1990-10-12 1997-03-01 Max Planck Gesellschaft Ribozimas modificadas.
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
EP1179340A3 (en) 1994-09-30 2003-05-07 INEX Pharmaceutical Corp. Compositions for the introduction of polyanionic materials into cells
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US6331524B1 (en) * 1994-12-09 2001-12-18 Genzyme Corporation Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy
US5948767A (en) 1994-12-09 1999-09-07 Genzyme Corporation Cationic amphiphile/DNA complexes
US5767099A (en) 1994-12-09 1998-06-16 Genzyme Corporation Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
US20020022264A1 (en) * 1995-05-26 2002-02-21 Sullivan Sean M. Delivery vehicles comprising stable lipid/nucleic acid complexes
US7422902B1 (en) * 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US6358523B1 (en) * 1996-12-06 2002-03-19 The Regents Of The University Of California Macromolecule-lipid complexes and methods for making and regulating
EP1109924A2 (en) 1998-09-09 2001-06-27 Genzyme Corporation Methylation of plasmid vectors
WO2002087541A1 (en) * 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Lipid-based formulations for gene transfer
CA2532228C (en) * 2003-07-16 2017-02-14 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
JP4764426B2 (ja) 2004-06-07 2011-09-07 プロチバ バイオセラピューティクス インコーポレイティッド カチオン性脂質および使用方法
US8598333B2 (en) * 2006-05-26 2013-12-03 Alnylam Pharmaceuticals, Inc. SiRNA silencing of genes expressed in cancer
US20080299177A1 (en) * 2007-06-06 2008-12-04 Biovaluation & Analysis, Inc. Supramolecular Complexes for Use in Acoustically Mediated Intracellular Drug Delivery in vivo
WO2011084721A2 (en) * 2009-12-21 2011-07-14 Agave Pharma Inc Cationic molecule and method of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050175682A1 (en) * 2003-09-15 2005-08-11 Protiva Biotherapeutics, Inc. Polyethyleneglycol-modified lipid compounds and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAYES, M. E. et al., Gene Therapy, 2006, vol. 13, pages 646-651 *
MEL'NIKOV, S. M. et al., Langmuir, 1999, vol. 15, pages 1923-1928 *

Also Published As

Publication number Publication date
WO2010135207A1 (en) 2010-11-25
CN102985548A (zh) 2013-03-20
EP2430168A4 (en) 2013-11-27
AU2010249881A1 (en) 2012-01-19
CN102985548B (zh) 2016-10-26
EP2430168A1 (en) 2012-03-21
US9080186B2 (en) 2015-07-14
JP2012526858A (ja) 2012-11-01
JP5675784B2 (ja) 2015-02-25
EP2430168B1 (en) 2016-12-21
CA2762095A1 (en) 2010-11-25
US20120289584A1 (en) 2012-11-15

Similar Documents

Publication Publication Date Title
AU2010249881B2 (en) Compositions comprising cationic amphiphiles and colipids for delivering therapeutics molecules
KR101762466B1 (ko) 지질, 지질 조성물 및 이의 사용 방법
EP2608785B1 (en) Lipomacrocycles and uses thereof
CN112533909A (zh) 维生素阳离子脂质
CN112424214A (zh) 包含甾族部分的阳离子脂质
EP4352038A2 (en) Ionizable cationic lipids for rna delivery
JP2022512945A (ja) 層間エステル、チオエステル、ジスルフィドおよび無水部分を含む２，５－ジオキソピペラジン脂質
CN114716355A (zh) 一种脂质化合物、包含其的组合物及应用
WO2023141624A1 (en) Ionizable lipids, lipid nanoparticles, and uses thereof
CN117658848A (zh) 递送治疗剂的脂质化合物及其应用
CN101475503A (zh) 一种新型阳离子类脂及其制备方法和应用
JP2025518221A (ja) 核酸の送達のための複合体
WO2025011532A1 (en) Lipid compounds for delivery of therapeutic agents and preparation method and its use thereof
JP6774965B2 (ja) カチオン性脂質としての化合物
JP2025530781A (ja) 新規のイオン化可能な脂質および脂質ナノ粒子ならびにそれらの使用方法
CN120051454A (zh) 用于递送生物活性成分的氨基脂质化合物和脂质纳米颗粒
WO2025043730A1 (en) Lipid compounds for delivery of therapeutic agents and preparation method and use thereof
WO2011084721A2 (en) Cationic molecule and method of use
WO2025256540A1 (en) Compositions and method for targeted gene delivery
WO2018062233A1 (ja) カチオン性脂質としての化合物
JP2018016642A (ja) 脂質粒子の製造法および脂質粒子を有する核酸送達キャリア
KR20260059895A (ko) 신규한 이온화 스테롤 유도체 및 이를 포함하는 지질 나노입자 조성물

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: AGAVE PHARMA, INCORPORATED

Free format text: FORMER APPLICANT(S): CUI, KUNYUAN; SWEEDLER, DAVID; LIANG, DONG

FGA Letters patent sealed or granted (standard patent)